Incidence, Prevalence and Outcomes of Acute Myocardial Infarction in Hospitalized Patients with Psoriasis: Results from the Nationwide Inpatient Sample Database

Authors

  • Christopher G. Gibson Department of Internal Medicine, Fairfield Medical Center, Lancaster, Ohio, USA
  • Bhakti B. Chavan Ohio University Heritage College of Osteopathic Medicine, Dublin, OH, USA
  • Ruby S. Gibson Long School of Medicine, University of Texas Health San Antonio, San Antonio, TX, USA
  • Francis Essien Department of Internal Medicine, Keesler Air Force Base, Biloxi, MS, USA
  • Melissa J. Newman Department of Internal Medicine, Fairfield Medical Center, Lancaster, Ohio, USA
  • Robert L. Zee Department of Internal Medicine, Fairfield Medical Center, Lancaster, Ohio, USA
  • Stephanie J. Ott Department of Rheumatology at the Fairfield Medical Center, Lancaster, OH, USA
  • Irving L. Rosenberg Department of Rheumatology at the Fairfield Medical Center, Lancaster, OH, USA

DOI:

https://doi.org/10.12970/2310-998X.2019.07.03

Keywords:

 Psoriasis, Epidemiology, Inflammation, Cardiovascular, Myocardial Infarction.

Abstract

Background: Psoriasis (PsO) is a chronic multisystem inflammatory condition that has been linked with increased cardiovascular mortality most notably in patients with a severe disease burden. This inflammatory process is driven by an increase in several markers including: C-reactive protein (CRP), cytokines, and acute phase reactants which promote the development and progression of atherosclerosis. Endothelial dysfunction is central to the disease pathophysiology and accelerated atherosclerosis results in a higher risk of Acute Myocardial Infarction (AMI), stroke and peripheral vascular disease (PVD). There is a paucity of literature describing the inpatient burden, prevalence, and socioeconomic status of hospitalized psoriasis patients diagnosed with AMI. The purpose of this article is to subsidize the literature by evaluating a nationwide database to compare the incidence, prevalence, and inpatient burden of AMI in patients with and without psoriasis.

Methods and Results: A total of 31,713 patients were diagnosed with PsO in a sample size of 7,135,090. Table 2 shows the distributions of sociodemographic characteristics and selected comorbid medical disorders for patients with psoriasis and patients in the comparison cohort. Patients with psoriasis demonstrated a statistically significant increased risk of AMI in adjusted and unadjusted analyses.

Conclusion: The correlation between atherosclerosis and aggressive therapy suggests that more vigorous therapy might decrease the likelihood and burden of atherosclerosis in patients with PsO and thus a lower incidence of AMI.

References

Gelfand JM, Troxel AB, Lewis JD, Kurd SK, Shin DB, Wang X, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 2007; 143: 1493-9. https://doi.org/10.1001/archderm.143.12.1493

Mallbris L, Akre O, Granath F, Yin L, Lindelof B, Ekbom A, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004; 19: 225-30. https://doi.org/10.1023/B:EJEP.0000020447.59150.f9

Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005; 352: 1685-1695. https://doi.org/10.1056/NEJMra043430

Koo J. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. Dermatol Clin 1996; 14: 485-96. https://doi.org/10.1016/S0733-8635(05)70376-4

Griffiths CE, Richards HL. Psychological influences in psoriasis. Clin Exp Dermatol 2001; 26: 338-42. https://doi.org/10.1046/j.1365-2230.2001.00834.x

Javitz HS, Ward MM, Farber E, Nail L, Vallow SG. The direct cost of care for psoriasis and psoriatic arthritis in the United States. J Am Acad Dermatol 2002; 46: 850-60. https://doi.org/10.1067/mjd.2002.119669

HCUP Databases. Healthcare Cost and Utilization Project (HCUP). 2015-2016. Agency for Healthcare Research and Quality, Rockville, MD. www.hcup-us.ahrq.gov/databases. jsp.

SAS Institute Inc 2013. SAS/ACCESS® 9.4 Interface to ADABAS: Reference. Cary, NC: SAS Institute Inc.

Neimann AL, Porter SB, Gelfand JM. Epidemiology of psoriasis. Expert Rev Dermatol 2006; 1: 63-75. https://doi.org/10.1586/17469872.1.1.63

Davidovici BB, Sattar N, Prinz J, et al. Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. J Invest Dermatol 2010; 130: 1785-96. https://doi.org/10.1038/jid.2010.103

Ghazizadeh R, Shimizu H, Tosa M, et al. Pathogenic mechanisms shared between psoriasis and cardiovascular disease. Int J Med Sci 2010; 7: 284-9. https://doi.org/10.7150/ijms.7.284

Ryan C, Kirby B. Psoriasis is a systemic disease with multiple cardiovascular and metabolic comorbidities. Dermatol Clin 2015; 33: 41-55. https://doi.org/10.1016/j.det.2014.09.004

McDonald CJ, Calabresi P. Occlusive vascular disease in psoriatic patients. N Engl J Med 1973; 288: 912. https://doi.org/10.1056/NEJM197304262881715

Havranek EP, Mujahid MS, Barr DA, et al. Social determinants of risk and outcomes for cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2015; 132: 873-898. https://doi.org/10.1161/CIR.0000000000000228

Tabas I, Garcia-Cardeña G, Owens GK. Recent insights into the cellular biology of atherosclerosis. J Cell Biol 2015; 209: 13-22. https://doi.org/10.1083/jcb.201412052

Downloads

Published

2019-03-25

Issue

Vol. 7 (2019)

Section

Articles